Aegerion Announces Resolution Of Warning Letter For JUXTAPID Capsules

(RTTNews) - Aegerion Pharmaceuticals Inc. (AEGR) announced that it has received a closeout letter from the Office of Prescription Drug Promotion or OPDP signifying the resolution of the Warning Letter in regard to statements made about JUXTAPID during two 2013 television broadcast interviews.

In light of corrective actions taken by Aegerion, including disseminating a corrective broadcast, OPDP considers the matter closed effective August 25, 2014.

"We worked closely with OPDP to resolve the issues raised in the Warning Letter and are pleased that OPDP considers the matter closed. We take very seriously our obligation to comply with all FDA requirements, including those pertaining to promotion of our product," said Martha Carter, Chief Regulatory Officer and Senior Vice President.